With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

Why did Trump order US chip sales halt to China? How did GameStop's Bitcoin purchase affect its stock? Why did Ford recall over one million vehicles? What impact will Trump’s tariffs have on retailers? How is Nvidia's upcoming earnings influenced by tariffs? Why is the new fiber optic cable improving Newark flights? What caused Macy’s to cut 2025 profit forecast? How will the Trump visa policy affect international students? Why is the EU delaying telecom rules overhaul?

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

benzinga.com/general/biotech/25/05/45629408/with-trials-in-motion-cash-to-2027-can-kyvernas-next-data-drop-turn-the-stock-around

HC Wainwright upgraded Kyverna Therapeutics Inc. (NASDAQ:KYTX), citing three upcoming data sets through mid-2025.
In its first quarter 2025 earnings released, the company highlighted:
Enrollment is complete in the registrational Phase 2 KYV-101 trial for stiff person syndrome (SPS).
The…

This story appeared on benzinga.com, 2025-05-27 19:42:54.